Comparison of effects of an aromatase inhibitor with human gonadotropin in clomiphene-resistant polycystic ovary syndrome

Comparison of therapeutic effect of aromatase inhibitor with human gonadotropin in patients with clomiphene-resistant polycystic ovary syndrome

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211120053119N1

Enrollment

120

Registered

2022-01-29

Start date

2021-12-06

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome, infertility. ????? ?????? ??? ??????

Interventions

Intervention 1: Intervention group: in the first step, Patients with induce ovulation were treated with clomiphene (50mg tablet produced by Iran Hormone Company), 100 mg daily from the 5th day of mens

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women with more than one year of infertility and clomiphene resistant polycystic ovary syndrome No significant underlying disease Has one or two open fallopian tubes Spouse normal spermogram

Exclusion criteria

Exclusion criteria: Age out of range Hypo or hyperthyroidism Hyperprolactinemia Anatomical problems of the uterus and fallopian tubes

Design outcomes

Primary

Measure	Time frame
Number of follicles. Timepoint: On the 16th Day of the menstrual cycle. Method of measurement: Vaginal ultrasound machine.;Pregnancy rate. Timepoint: one month. Method of measurement: blood test.;Endometrial Thickness. Timepoint: On the 16th Day of the menstrual cycle. Method of measurement: Vaginal ultrasound machine.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Dadkhah

Iran University of Medical Sciences

mdadkhah27@yahoo.com+98 21 8670 2220

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026